EXTRASYNTHESE SAS

Their core work

EXTRASYNTHESE is a French specialty chemistry SME that produces and supplies plant-derived secondary metabolites and custom bioactive compounds for research and biomedical applications. In the ENDOSCAPE project, they contributed their core competency — production of plant secondary metabolites and click chemistry expertise — to develop endosomal escape enhancers for non-viral gene delivery systems. In SynBio4Flav, they extended their natural product focus into synthetic biology, supporting the engineering of microbial consortia to produce flavonoids using organisms such as P. putida, E. coli, S. albus, and S. cerevisiae. Their value to consortia lies in the intersection of plant chemistry know-how and bioprocess development, translating natural compound production from plant extraction toward engineered biological manufacturing.

What they specialise in

How they've shifted over time

Both H2020 projects launched simultaneously in 2019, so the evolution reflects thematic diversification rather than a shift over years: ENDOSCAPE anchors their traditional identity in plant metabolite production and medicinal chemistry (click chemistry, endosomal escape), while SynBio4Flav signals a move toward synthetic biology and fermentation-based biomanufacturing as a route to the same compound classes. The trend is a deliberate migration from extraction-based natural product supply toward engineered biosynthesis — using microbial chassis to produce flavonoids and other plant-like molecules at scale. This positions them at the interface of their established chemistry expertise and the emerging bioeconomy.

EXTRASYNTHESE appears to be transitioning from classical natural product extraction and supply toward synthetic biology-enabled bioproduction, making them increasingly relevant to industrial biotechnology and green chemistry consortia.

How they like to work

EXTRASYNTHESE joins projects strictly as a specialist partner — they have never coordinated an H2020 project — which is consistent with a small supplier whose value is precise technical contribution rather than project management. Across two projects they engaged with 22 unique partners in 9 countries, suggesting they are comfortable in mid-to-large international consortia and are sought out for a specific chemistry capability. There is no sign of repeat partnerships, indicating they are brought in on a project-by-project basis for their niche expertise rather than as part of a fixed research alliance.

With 22 unique consortium partners spread across 9 countries in just two projects, EXTRASYNTHESE has built a broad European network relative to their project volume. Their geographic spread suggests active engagement across Western and Central European research communities rather than a purely domestic French collaboration base.

What sets them apart

EXTRASYNTHESE occupies a rare niche as a commercial supplier of plant-derived reference standards and specialty chemicals that has successfully bridged into EU-funded biomedical and synthetic biology research. Most companies of this type remain purely commercial; EXTRASYNTHESE has demonstrated they can contribute production process development and chemical expertise directly within research consortia. For consortium builders, they offer a commercially grounded partner who can translate laboratory-scale production protocols into scalable, reproducible compound supply — a capability that academic partners typically cannot provide.

Highlights from their portfolio

• ENDOSCAPE
  Their highest-funded project (€472,500), directly applying plant secondary metabolite production to a clinically relevant gene therapy challenge — a striking example of natural product chemistry meeting precision medicine.
• SynBio4Flav
  Signals their strategic move into synthetic biology, using four distinct microbial chassis to produce functionalized flavonoids — a significant thematic expansion beyond their core extraction-based chemistry.